共 50 条
- [41] Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trialLANCET ONCOLOGY, 2021, 22 (05): : 643 - 654Eggermont, Alexander M. M.Blank, Christian U.Mandala, MarioLong, Georgina, VAtkinson, Victoria G.Dalle, StephaneHaydon, Andrew M.Meshcheryakov, AndreyKhattak, AdnanCarlino, Matteo S.Sandhu, ShahneenLarkin, JamesPuig, SusanaAscierto, Paolo A.Rutkowski, PiotrSchadendorf, DirkKoornstra, RutgerHernandez-Aya, LeonelGiacomo, Anna Maria Divan den Eertwegh, Alfonsus J. M.Grob, Jean-JacquesGutzmer, RalfJamal, RahimaLorigan, Paul C.van Akkooi, Alexander C. J.Krepler, ClemensIbrahim, NageatteMarreaud, SandrineKicinski, MichalSuciu, StefanRobert, Caroline
- [42] Adjuvant pembrolizumab or placebo in patients with high-risk, locally advanced cutaneous squamous cell carcinoma: Phase 3 KEYNOTE-630CANCER RESEARCH, 2020, 80 (16)Chang, Anne Lynne S.Daniels, Gregory A.Cohen, Ezra E.Ge, Joy YangGumuscu, BurakSwaby, Ramona F.Geiger, Jessica L.
- [43] The role of interferon alfa-2b adjuvant therapy of high risk resected melanoma stage I & II.PROCEEDINGS EUROSURGERY 2000, 2000, : 141 - 144Economou, GKKoletsis, ENFilopoulos, E
- [44] Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase 3 trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Eggermont, Alexander M.Meshcheryakov, AndreyAtkinson, VictoriaBlank, Christian U.Mandala, MarioLong, Georgina V.Barrow, CatherineDi Giacomo, Anna MariaStephens, RosalieSandhu, Shahneen KaurKudchadkar, Ragini ReineyOrtiz-Romero, Pablo L.Svane, Inge MarieVan Akkooi, Alexander Christopher JonathanKrepler, ClemensIbrahim, NageatteMarreaud, SandrineKicinski, MichalSuciu, StefanRobert, Caroline
- [45] Phase 3 study of pembrolizumab vs placebo as adjuvant therapy for patients with renal cell carcinoma (RCC): KEYNOTE-564 Asia subsetASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 63 - 64Park, Se HoonChang, Yen-HwaLee, Jae LyunKitamura, HiroshiChung, JinsooNishimura, KazuoKato, MinoruKato, HaruakiKimura, GoMasumori, NaoyaChiu, Kun-YuanChang, Chao-HsiangNumakura, KazuyukiChen ChangBurgents, Joseph E.Willemann-Rogerio, JaquelineChoueiri, Toni
- [46] Neoadjuvant pembrolizumab plus chemotherapy vs placebo plus chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: Post hoc analysis of adjuvant radiation therapy in the phase 3 KEYNOTE-522 studyCANCER RESEARCH, 2023, 83 (05)McArthur, HeatherCortes, JavierDent, RebeccaO'Shaughnessy, JoycePusztai, LajosKuemmel, SherkoFoukakis, TheodorosPark, Yeon HeeHui, RinaHarbeck, NadiaTakahashi, MasatoUntch, MichaelFasching, Peter A.Cardoso, FatimaDenkert, CarstenZhu, YalinDing, YuPan, WilburSchmid, Peter
- [47] Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trialLANCET ONCOLOGY, 2021, 22 (05): : 655 - 664Bottomley, AndrewCoens, CorneelMierzynska, JustynaBlank, Christian U.Mandala, MarioLong, Georgina, VAtkinson, Victoria G.Dalle, StephaneHaydon, Andrew M.Meshcheryakov, AndreyKhattak, AdnanCarlino, Matteo S.Sandhu, ShahneenPuig, SusanaAscierto, Paolo A.Larkin, JamesLorigan, Paul C.Rutkowski, PiotrSchadendorf, DirkKoornstra, RutgerHernandez-Aya, LeonelDi Giacomo, Anna Mariavan den Eertwegh, Alfonsus J. M.Grob, Jean-JacquesGutzmer, RalfJamal, Rahimavan Akkooi, Alexander C. J.Krepler, ClemensIbrahim, NageatteMarreaud, SandrineKicinski, MichalSuciu, StefanRobert, CarolineEggermont, Alexander M. M.
- [48] Adjuvant pembrolizumab versus high-dose interferon α-2b for Chinese patients with resected stage III melanoma: a retrospective cohort studyINVESTIGATIONAL NEW DRUGS, 2020, 38 (05) : 1334 - 1341Li, TaoJia, Dong-DongTeng, Li-Song
- [49] Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trialLANCET ONCOLOGY, 2022, 23 (10): : 1274 - 1286O'Brien, MaryPaz-Ares, LuisMarreaud, SandrineDafni, UraniaOselin, KerstiHavel, LiborEsteban, EmilioIsla, DoloresMartinez-Marti, AlexFaehling, MartinTsuboi, MasahiroLee, Jong-SeokNakagawa, KazuhikoYang, JingSamkari, AymanKeller, Steven M.Mauer, MurielleJha, NitishStahel, RolfBesse, BenjaminPeters, Solange
- [50] Neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for earlystage high-risk ER+/HER2-breast cancer: Results from the phase 3 KEYNOTE-756 studyEUROPEAN JOURNAL OF CANCER, 2024, 200 : 10 - 11Cardoso, F.O'Shaughnessy, J.McArthur, H.Schmid, P.Cortes, J.Harbeck, N.Telli, M. L.Cescon, D. W.Fasching, P.Shao, Z.Loirat, D.Park, Y. H.Gonzalez Fernandez, M.Rubovszky, G.Im, S. A.Hui, R.Takano, T.Andre, F.Yasojima, H.Liu, Z.Ding, Y.Jia, L.Karantza, V.Tryfonidis, K.Bardia, A.